Morgan Stanley’s OptiNose OPTN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-4,770
| Closed | -$43.7K | – | 8225 |
|
|
2025
Q1 | $43.7K | Buy |
4,770
+2,493
| +109% | +$15.6K | ﹤0.01% | 6316 |
|
|
2024
Q4 | $15.2K | Sell |
2,277
-3,335
| -59% | -$29.4K | ﹤0.01% | 6654 |
|
|
2024
Q3 | $56.4K | Sell |
5,612
-3,341
| -37% | -$48.7K | ﹤0.01% | 6184 |
|
|
2024
Q2 | $140K | Sell |
8,953
-3,192
| -26% | -$53.5K | ﹤0.01% | 5831 |
|
|
2024
Q1 | $266K | Sell |
12,145
-19,495
| -62% | -$433K | ﹤0.01% | 5615 |
|
|
2023
Q4 | $612K | Buy |
31,640
+18,627
| +143% | +$340K | ﹤0.01% | 5541 |
|
|
2023
Q3 | $240K | Sell |
13,013
-5,943
| -31% | -$107K | ﹤0.01% | 5504 |
|
|
2023
Q2 | $350K | Buy |
18,956
+6,408
| +51% | +$152K | ﹤0.01% | 5396 |
|
|
2023
Q1 | $363K | Buy |
12,548
+3,975
| +46% | +$106K | ﹤0.01% | 5436 |
|
|
2022
Q4 | $238K | Buy |
8,573
+3,110
| +57% | +$118K | ﹤0.01% | 5593 |
|
|
2022
Q3 | $300K | Sell |
5,463
-211
| -4% | -$11.6K | ﹤0.01% | 5532 |
|
|
2022
Q2 | $312K | Sell |
5,674
-11,104
| -66% | -$408K | ﹤0.01% | 5663 |
|
|
2022
Q1 | $621K | Sell |
16,778
-370
| -2% | -$13.2K | ﹤0.01% | 5280 |
|
|
2021
Q4 | $417K | Sell |
17,148
-4,670
| -21% | -$156K | ﹤0.01% | 5657 |
|
|
2021
Q3 | $982K | Sell |
21,818
-8,114
| -27% | -$340K | ﹤0.01% | 5051 |
|
|
2021
Q2 | $1.4M | Buy |
29,932
+29,324
| +4,823% | +$1.5M | ﹤0.01% | 4886 |
|
|
2021
Q1 | $34K | Sell |
608
-29,228
| -98% | -$1.78M | ﹤0.01% | 6527 |
|
|
2020
Q4 | $1.85M | Buy |
29,836
+20,673
| +226% | +$1.27M | ﹤0.01% | 4228 |
|
|
2020
Q3 | $535K | Sell |
9,163
-8,290
| -47% | -$614K | ﹤0.01% | 4610 |
|
|
2020
Q2 | $1.95M | Buy |
17,453
+16,975
| +3,551% | +$1.21M | ﹤0.01% | 3627 |
|
|
2020
Q1 | $32K | Sell |
478
-17,464
| -97% | -$1.76M | ﹤0.01% | 5637 |
|
|
2019
Q4 | $2.48M | Buy |
17,942
+17,230
| +2,420% | +$2.23M | ﹤0.01% | 3870 |
|
|
2019
Q3 | $75K | Buy |
712
+536
| +305% | +$53.5K | ﹤0.01% | 5547 |
|
|
2019
Q2 | $19K | Sell |
176
-223
| -56% | -$29.4K | ﹤0.01% | 5953 |
|
|
2019
Q1 | $61K | Sell |
399
-1,759
| -82% | -$204K | ﹤0.01% | 5580 |
|
|
2018
Q4 | $201K | Sell |
2,158
-499
| -19% | -$71.3K | ﹤0.01% | 5285 |
|
|
2018
Q3 | $496K | Sell |
2,657
-128
| -5% | -$36.5K | ﹤0.01% | 5009 |
|
|
2018
Q2 | $1.17M | Buy |
2,785
+1,771
| +175% | +$597K | ﹤0.01% | 4515 |
|
|
2018
Q1 | $305K | Buy |
1,014
+341
| +51% | +$94.5K | ﹤0.01% | 5276 |
|
|
2017
Q4 | $190K | Buy |
+673
| New | +$189K | ﹤0.01% | 5427 |
|
Morgan Stanley's OPTN Position: Q2 2025 in Review
Morgan Stanley sold out of OptiNose (OPTN) in Q2 2025, closing a stake of 4,770 shares — an estimated $43.7K sold.
Morgan Stanley first reported a position in OPTN in Q4 2017 and held it in 30 quarters. The position peaked at $2.48M in Q4 2019. 0 funds tracked by Wall St. Rank hold OPTN as of Q2 2025.
- Morgan Stanley reported no remaining OptiNose position as of Q2 2025 after selling out during the quarter.
- Morgan Stanley sold 4,770 OptiNose shares in Q2 2025, an estimated $43.7K.
- Morgan Stanley first reported a position in OptiNose in Q4 2017 and held it in 30 quarters.
- Morgan Stanley's OptiNose position peaked at $2.48M in Q4 2019.
- 0 funds tracked by Wall St. Rank held OptiNose as of Q2 2025.
Based on Morgan Stanley's 13F filing for Q2 2025, filed 15 Aug 2025.